CHEK2 and diffuse large B-cell lymphoma: As expected, ixazomib in combination with a CHK2 inhibitor (CHK2i) showed synergistic activity in DLBCL cell lines that were more sensitive to ixazomib (RC, MZ, and HT), but not in cells that were more resistant to ixazomib (U-2932) (Figure 5B; see Supplementary Figure 4 for detailed synergy calculations).